Transcutaneous supraorbital neurostimulation in “de novo” patients with migraine without aura: the first Italian experience

The Journal of Headache and Pain

Research Article

Laura Marcuccio¹  Antonio Russo¹  Francesca Conte¹  Gioacchino Tedeschi¹  Alessandro Tessitore¹  Alfonso Giordano² 

[1] Headache Center, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, 80138, Naples, Italy;MRI Research Center SUN-FISM, Second University of Naples, Naples, Italy;MRI Research Center SUN-FISM, Second University of Naples, Naples, Italy;Institute for Diagnosis and Care “Hermitage Capodimonte”, Naples, Italy;

关键词: Migraine;    Transcutaneous supraorbital neurostimulation;    tSNS;    Therapy;    Cefaly;   

DOI  :  10.1186/s10194-015-0551-3

 received in 2015-05-27, accepted in 2015-07-02,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundTranscutaneous supraorbital neurostimulation (tSNS) has been recently found superior to sham stimulation for episodic migraine prevention in a randomized trial. We evaluated both the safety and efficacy of a brief period of tSNS in a group of patients with migraine without aura (MwoA).MethodsWe enrolled 24 consecutive patients with MwoA experiencing a low frequency of attacks, which had never taken migraine preventive drugs in the course of their life. Patients performed a high frequency tSNS and were considered “compliant” if they used the tSNS for ≥ 2/3 of the total time expected. For this reason, four patients were excluded from the final statistical analysis. Primary outcome measures were the reduction migraine attacks and migraine days per month (p < 0.05). Furthermore, we evaluated the percentage of patients having at least 50 % reduction of monthly migraine attacks and migraine days. Secondary outcome measures were the reduction of headache severity during migraine attacks and HIT-6 (Headache Impact Test) rating as well as in monthly intake of rescue medication (p < 0.05). Finally, compliance and satisfaction to treatment and potential adverse effects related to tSNS have been evaluated.ResultsBetween run-in and second month of tSNS treatment, both primary and secondary endpoints were met. Indeed, we observed a statistically significant decrease in the frequency of migraine attacks (p < 0.001) and migraine days (p < 0.001) per month. We also demonstrated at least 50 % reduction of monthly migraine attacks and migraine days in respectively 81 and 75 % of patients. Furthermore, a statistically significant reduction in average of pain intensity during migraine attacks (p = 0.002) and HIT-6 rating (p < 0.001) and intake of rescue medication (p < 0.001) has been shown. All patients showed good compliance levels and no relevant adverse events.ConclusionIn patients experiencing a low frequency of attacks, significant improvements in multiple migraine severity parameters were observed following a brief period of high frequency tSNS. Therefore, tSNS may be considered a valid option for the preventive treatment of migraine attacks in patients who cannot or are not willing to take daily medications, or in whom low migraine frequency and/or intensity would not require pharmacological preventive therapies.

【 授权许可】

Unknown   
© Russo et al. 2015. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.